Globalisation of US cancer trials is reducing enrolment of Black patients, study finds
The increasing globalisation of US-initiated cancer clinical trials is linked to lower enrolment of Black patients, a new study has found.
Outsourcing
OCT West Coast: key points on engaging patients and advocacy groups
Patient advocacy groups are fast becoming the new influencers in the clinical trials space. At...
OCT West Coast: IQVIA’s Nagaraja Srivatsan talks decentralised trials and the future of clinical research
Decentralised clinical trials, and the digital technologies that facilitate them, have been a lifeline for...
A case for streamlined RFIs in the pharmaceutical industry
External suppliers are used extensively throughout the pharma industry, but how can new client-supplier relationships...
Alexander O’Leary Q&A: how are clinical trial sponsors’ outsourcing activities evolving?
Outsourcing is an important means for clinical trial sponsors to bring in outside expertise, from...
Scientist.com rolls out trial data analytics solution
Scientist.com has introduced a digital reporting solution, dubbed Trial Insights, to provider researchers with on-demand insights into clinical trials. The analytics solution is the first direct service by the company,…
MDMA Treatments Found to Eliminate PTSD Symptoms in Phase II Trial
Gavin Davidson, CVMD Analyst, GlobalData, examines how MDMA is used to treat patients with PTSD
How to Enable Greater Budget Forecasting
Ken Olovich, R.Ph., MBA, Sourcing and Financial Director of Chorus, Eli Lilly, explains a model of budget transparency with CROs to enable better budget forecasting
Poor Communication Can Cost You – REALLY Cost You
Daria Wicks, Director, Clinical Operations, Vericel Corporation, emphasizes the importance of clear communication within an organization
To Outsource or Not to Outsource? That is the Question
Lisa Henry, Manager of Clinical Research, Cordis, discusses the merits of clinical trial outsourcing models
Execution: A Key Success Factor in All Sponsor-CRO Collaborations
Ken Getz, Tufts CSDD, examines why the sponsor-CRO dynamic often falls short of expectations
